Labcorp announced the launch and immediate availability of its test to identify the presence or absence of phosphorylated tau 217 (pTau217), a pivotal blood biomarker designed to aid in the diagnosis of Alzheimer's disease and the subsequent monitoring of patients undergoing treatment with new Alzheimer's disease therapies. Labcorp's pTau217 test can be ordered by physicians and used in clinical trials and research by global biopharmaceutical partners. Alzheimer's disease, the most prevalent form of dementia, poses a significant health challenge globally.

An estimated 6.7 million Americans are currently living with Alzheimer's disease, a figure projected to more than double to 13.8 million individuals by 2060. The pTau217 marker has been used in Alzheimer's drug trials to monitor patients on anti-amyloid therapy. Labcorp's introduction of pTau217 as a standalone test marks a significant advancement in the company's Alzheimer's testing portfolio, complementing its existing array of blood-based biomarker testing, including: Beta amyloid 42/40 ratio, which provides an indication of amyloid pathology for Alzheimer's disease and is available nationwide for clinicians and available in Europe as a CE-marked assay.

Neurofilament light chain (NfL), which provides an indication of disease severity by measuring current levels of neurodegeneration. ATN Profile, which combines three blood biomarkers ? beta amyloid 42/40, NfL and pTau181.

The ATN Profile provides physicians with an accessible and interpretable blood test to assess pathologies associated with Alzheimer's disease and other neurodegenerative conditions, which can help accelerate the path to diagnosis and intervention.